



# Results analysis: BH Macro (BHMG)

Whilst BHMG delivers a flat return for 2025, the board retain full confidence...

Update  
02 April 2026

- **BH Macro’s (BHMG) investment objective is to generate long-term appreciation through active trading on a global macro basis by investing in the Brevan Howard Master Fund Limited (the “Master Fund”). During 2025, BH Macro’s NAV per share for the Sterling Class shares rose by 1.38%, and that of the US Dollar Class shares by 0.83%. The share price performance was lower for both share classes at -1.72% for the Sterling Class shares and 1.68% for the US Dollar Class shares.**
- **Despite £116m having been spent during 2025 under the buyback program, including US Dollar buybacks of US\$1.3m, this was not sufficient to prevent the average discount for the year being 8.10% for the Sterling Class shares and 8.36% for the US Dollar Class shares. Consequently, class closure votes were called for February 2026. In the event, those shareholders who voted did so decisively against class closure, with 96.23% of those who voted, voting against for GBP shares and 99.91% for USD shares.**
- **The company’s ongoing charges ratio, which includes both management and performance fees and Master Fund charges, for the financial year ended 2025 as compared to the ongoing charges ratio for the financial year ended 2024 has decreased from 2.95% to 2.47% on the Sterling shares and decreased from 3.06% to 2.40% on the US Dollar shares, primarily due to changes in the level of the manager’s performance fee as a result of relative performance.”**
- **The board regards the company’s performance during 2025 as less than satisfactory as does Brevan Howard Capital Management LP (the manager) – whilst it is within expected bounds of return. The board are encouraged by the changes to process which the manager has implemented during the course of the year.**
- **In addressing the persistent level of discount, the board has negotiated an increase in the 2026 allowance for Master Fund redemptions to enable buybacks to up to 14.99% of each class of the company’s issued share capital (as at the end of 2025), without fees being incurred, up from 5% in 2025.**
- **On 26 January 2026, it was announced that a private Brevan Howard fund was being launched which will have the power to invest in the shares of both the Master Fund and BH**

## Analysts:

**William Heathcoat Amory**

+44 (0)203 384 8795



*Kepler Partners is not authorised to make recommendations to Retail Clients. This report is based on factual information only.*

*The material contained on this site is factual and provided for general informational purposes only. It is not an invitation or inducement to buy, sell or subscribe to any product described, nor is it a statement as to the suitability or otherwise of any investments for any person. The material on this site does not constitute a financial promotion within the meaning of the FCA rules or the financial promotions order. Persons wishing to invest in any of the securities discussed in the website should take their own independent advice with regard to the suitability of such investments and the tax consequences of such investment.*

**Macro, along with other products offered by Brevan Howard. Therefore, there will be an additional potential purchaser of the company’s shares.**

- **The macro-economic and geopolitical background remains extremely challenging. While this is undoubtedly a very difficult environment for individuals to experience and live through, the board believes it will provide opportunities for the manager to deliver returns in the future.**
- **Richard Horlick, chairman said “BH Macro has historically provided significant diversification from, and lack of correlation to, bond and equity markets. In today’s unpredictable global market environment, macro strategies such as BH Macro have never been more relevant. Whilst the board regards the company’s performance for 2025 as less than satisfactory (as does the manager), NAV returns were within expected bounds of return and proved the convexity of trades for which Brevan Howard are well known**



**(i.e. when “they get it wrong” the downside risk of the NAV is limited, and on the other hand being able to capture plenty of upside when they are correct). As a board, we are confident that the actions we and the manager have taken are the best way to address the issues facing our shareholders, and as such, the board retains its confidence in the manager and the company’s strategy during these challenging times.”**

Whilst BH Macro’s NAV and share price returns have been disappointing in absolute and relative terms during the year, it is worth remembering that in our view, BH Macro GBP Shares (ticker = “BHMG”) has two potential roles in a portfolio. Firstly, we believe it can act as a low volatility compounder, which can form a core part of a long-term investment portfolio. Secondly, it can act as a strong diversifier within equity and bond portfolios. The key to both is that what BHMG delivers to investors is very different, and hopefully complimentary, to the returns from equity and bond markets.

As it was, equity markets around the world had a hallmark year in terms of performance during 2025. In this context, it is perhaps no surprise that BHMG did not contribute to overall returns. It wasn’t all plain sailing for equity markets however. When President Trump made his “Liberation Day” announcements in early April, equity markets globally fell precipitously. The positive returns that BHMG delivered during April 2025 contrasted with high volatility in equity markets, serving to remind investors that BHMG can act as a diversifier, or shock absorber, in equity portfolios. In our view, this diversifier potential continues to be one of the main attractions of BHMG to shareholders, particularly in light of an increasing volatile market backdrop in 2026.

Set against a difficult market for investment trusts generally, the discount to NAV has remained stubbornly wide despite the board’s ongoing efforts. The prospects for a narrower discount on a sustained basis have clearly improved, with the board now having greater firepower to buy shares back of up to 14.99% of shares in issue without incurring an extra fee. At the same time, whilst precise details are relatively scarce, the launch of a new fund by the manager with the potential to invest in BHMG’s shares at a discount, must also be seen as encouraging.

Since the period end, a decisive majority of voting shareholders in each of the company’s two share classes again voted against class closure resolutions. In our view, this continues to demonstrate ongoing investor conviction in BH Macro’s unique proposition, and exposure to a diversifying macro hedge fund strategy. NAV performance during the first two months of 2026 was relatively strong, though the war in Iran has evidently wrongfooted the manager and has given back this strong performance. At the time of writing, BHMG’s sterling NAV is -0.2% YTD. The repercussions of Trump’s action will be felt in years to

come in different ways and in different countries around the world. Historically, diverging central bank responses to an economic shock such as that posed by the war in Iran have been a rich seam of opportunity for macro traders. With the discount still wide in absolute terms, creating in our view an attractive entry point, BHMG may start to contribute more positively in portfolios in 2026.

[Click here to read our latest research on BHMG](#)

[Click here to read the FY report on RNS](#)

[Click here to add BHMG to your watchlist](#)



## Disclaimer

---

**Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.**

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm's internal rules. A copy of the firm's Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 70 Conduit Street, London W1S 2GF with registered number OC334771.

